NCT02227693View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 1, 2015

Study Completion Date

April 1, 2015

Conditions

Thrombocytopenia Associated With Chronic Liver Disease

Interventions

DRUG

avatrombopag

E5501 (avatrombopag) 20-mg tablets

DRUG

Placebo

Placebo matching 20-mg tablets

Trial Locations (14)

Unknown

Matsuyama

Iizuka

Kitakyushu

Kurume

Kure

Sapporo

Sagamihara

Ikeda

Takatsuki

Minato-Ku

Fukuoka

Kumamoto

Osaka

Yamanashi

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT02227693 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia | Biotech Hunter | Biotech Hunter